Related Experiment Video
Updated: Jan 15, 2026

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
Published on: May 9, 2025
Concentrated Micronized Fat Ameliorates Skin Fibrosis in Bleomycin-Induced Murine Model and Enhances Fat Graft
Xuan Ma1, Miao Dong1, Ningbei Yin2
1Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 33 Badachu Road, Shijingshan District, Beijing, 100144, People's Republic of China.
Background:
Scleroderma is characterized by fibrosis of the skin and internal organs, vascular abnormalities, and immune dysregulation. Fat grafting has emerged as a promising therapeutic approach for improving soft tissue deficits and alleviating fibrosis in scleroderma patients. However, low fat graft survival and unresolved fibrosis in fibrotic tissues limit its efficacy. This study aims to evaluate the efficacy of Concentrated Micronized Fat (CMF), a mechanically processed fat product enriched with stromal vascular fraction (SVF) cells and intact adipocytes, in mitigating bleomycin-induced skin fibrosis and enhancing fat graft survival.
Method:
CMF was prepared using a mechanical micronization and filtration-adsorption method to enrich stromal vascular fraction cells while retaining intact adipocytes. In vitro experiments assessed the effects of CMF on fibroblast proliferation and migration. A murine model of bleomycin (BLM)-induced skin fibrosis was established, and the therapeutic effects of CMF and Coleman fat were compared through in vivo transplantation.
Result:
In vitro experiments showed that CMF significantly inhibited fibroblast proliferation and migration. In vivo, CMF transplantation effectively mitigated bleomycin-induced dermal thickening and collagen deposition while promoting adipocyte survival.
Conclusion:
CMF effectively alleviates skin fibrosis. It improves fat graft retention under fibrotic conditions. These results suggest that CMF is a promising therapeutic approach for treating scleroderma-related fibrosis.
No Level Assigned:
This journal requires that authors assign a level of evidence to each submission to which Evidence-Based Medicine rankings are applicable. This excludes Review Articles, Book Reviews, and manuscripts that concern Basic Science, Animal Studies, Cadaver Studies, and Experimental Studies. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
More Related Videos
06:52Induction of Mouse Lung Injury by Endotracheal Injection of Bleomycin
Published on: April 30, 2019
07:38A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice
Published on: April 13, 2018